These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25074845)

  • 1. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.
    Kim HS; Kim JH; Yang I
    Lung Cancer; 2014 Sep; 85(3):385-9. PubMed ID: 25074845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer.
    Kim HS; Kim JW; Kim JH; Choi DR; Han AR; Kim MJ; Kim BC; Zang DY
    Oncology; 2015; 88(2):69-75. PubMed ID: 25277674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.
    Knollmann FD; Kumthekar R; Fetzer D; Socinski MA
    Clin Lung Cancer; 2014 Mar; 15(2):103-9. PubMed ID: 24361250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.
    Jang HJ; Cho JW; Park B; Choi HC; Kim HS; Kim JH
    J Cancer; 2015; 6(2):169-76. PubMed ID: 25561982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.
    Jung SG; Kim JH; Kim HS; Kim KJ; Yang I
    Chin J Cancer Res; 2016 Apr; 28(2):161-7. PubMed ID: 27199513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ideal number of target lesions per organ to measure in metastatic colorectal cancer.
    Kim HS; Kim JH
    Oncol Lett; 2014 Oct; 8(4):1896-1900. PubMed ID: 25202433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
    Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD
    Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
    Sun JM; Ahn MJ; Park MJ; Yi JH; Kim TS; Chung MJ; Park YH; Ahn JS; Park K
    Lung Cancer; 2010 Jul; 69(1):105-9. PubMed ID: 19959251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.
    Birchard KR; Hoang JK; Herndon JE; Patz EF
    Cancer; 2009 Feb; 115(3):581-6. PubMed ID: 19117348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.
    Toffart AC; Moro-Sibilot D; Couraud S; Merle P; Perol M; Girard N; Souquet PJ; Mastroianni B; Ferretti GR; Romand P; Chatellain P; Vesin A; Brambilla E; Brambilla C; Timsit JF
    BMC Cancer; 2014 Dec; 14():989. PubMed ID: 25527907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
    Erasmus JJ; Gladish GW; Broemeling L; Sabloff BS; Truong MT; Herbst RS; Munden RF
    J Clin Oncol; 2003 Jul; 21(13):2574-82. PubMed ID: 12829678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.
    Zhou T; Zheng L; Hu Z; Zhang Y; Fang W; Zhao Y; Ge J; Zhao H; Zhang L
    Sci Rep; 2015 Jan; 5():7683. PubMed ID: 25567662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
    Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
    Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
    Wu YL; Fukuoka M; Mok TS; Saijo N; Thongprasert S; Yang JC; Chu DT; Yang JJ; Rukazenkov Y
    Lung Cancer; 2013 Aug; 81(2):280-7. PubMed ID: 23540718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.
    Choi HC; Kim JH; Kim HS; Jung SG; Hwang SM; Ju SB; Yang I
    J Cancer; 2015; 6(7):652-7. PubMed ID: 26078796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
    Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor.
    Egger ME; Cannon RM; Metzger TL; Nowacki M; Kelly L; Tatum C; Scoggins CR; Callender GG; McMasters KM; Martin RC
    J Am Coll Surg; 2013 Apr; 216(4):845-56; discussion 856-7. PubMed ID: 23415549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.
    Nishino M; Jackman DM; Hatabu H; Yeap BY; Cioffredi LA; Yap JT; Jänne PA; Johnson BE; Van den Abbeele AD
    AJR Am J Roentgenol; 2010 Sep; 195(3):W221-8. PubMed ID: 20729419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.